Obesity coverage on Peptide News Digest follows the drugs that actually reshape body weight at scale: GLP-1 agonists, GIP/GLP-1 dual and triple agonists, amylin combinations, and the next layer behind them.
Headline reads from 2025 and 2026: SURMOUNT-5 (tirzepatide vs semaglutide head-to-head), ACHIEVE-3 (orforglipron in obesity), REDEFINE-1 (CagriSema), the SELECT cardiovascular outcomes trial in non-diabetic adults with obesity, and a steady stream of real-world evidence showing the gap between trial weight loss and 12-month routine-care outcomes. Adherence and discontinuation are now the most cited weak points in the category.
The other half of obesity coverage is access — payer policy, Medicare and CMS rulings, the compounding economy, telehealth distribution, and the OMA conference circuit. Browse the latest below.
Kalohexis, the melanocortin-receptor peptide biotech spun out of Endevica Bio in March 2026, filed a confidential IPO application with the SEC this week. The company advances two lead assets on the melanocortin platform: 710GO, an oral dual MC3R/MC4R agonist that entered Phase 1 testing in Q2 2026 for general obesity; and mifomelatide, a dual MC3R/MC4R antagonist in Phase 2 development for cancer cachexia (severe weight loss and muscle wasting in patients with advanced cancer). The two programs run in opposite pharmacological directions on the same receptor family: 710GO activates MC3R/MC4R to reduce food intake and produce weight loss; mifomelatide blocks MC3R/MC4R to reverse cachexia-driven weight loss. Kalohexis's Nature Communications publication (June 2026) demonstrated that dual MC3R/MC4R activation drove substantial weight loss and reduced food intake in nonhuman primates without the cardiovascular safety risks that limited earlier melanocortin drug candidates. Data was also presented at ENDO 2026. The IPO filing signals investor appetite for non-GLP-1 obesity mechanisms as the melanocortin pathway becomes the highest-profile alternative to incretin biology.
On July 7, Kailera Therapeutics reported positive topline results from two Hengrui Pharma Phase 3 trials in China of HRS-7535/KAI-7535, a once-daily oral small-molecule GLP-1 receptor agonist licensed to Kailera outside Greater China. In HARBOR-1, 556 adults with obesity or overweight lost a mean 9.5% of body weight at 120 mg and 10.9% at 180 mg by week 44. OUTSTAND-2, in 810 adults with type 2 diabetes, showed HbA1c reductions of 1.50% to 1.68% and non-inferiority versus dapagliflozin. Hengrui plans China NDA filings; Kailera is running a parallel global Phase 2.
On July 5, Ascletis submitted two INDs to the FDA: ASC36, a peptide amylin receptor agonist dosed once monthly to once quarterly by injection, and ASC36_35, a co-formulation pairing ASC36 with the GLP-1R/GIPR agonist peptide ASC35. In diet-induced obese rat studies, ASC36 monotherapy showed roughly 91% and 32% greater relative body-weight reduction than petrelintide and eloralintide, and the ASC36_35 combination showed about 51% greater reduction than co-administered eloralintide plus tirzepatide. The filings push amylin biology further into the obesity race.
Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.
Pep2Tango Therapeutics presented preclinical data on PTT-A, a novel long-acting unimolecular peptide tetra-agonist activating the GLP-1, GIP, amylin, and calcitonin receptors simultaneously, in a Medscape 'Moving Beyond GLP-1s' feature drawing from the ADA 2026 session 'Novel Strategies for Obesity Pharmacology' (oral abstracts 85-OR and 299-OR, Diabetes journal supplement). In 21-day chronic studies in diet-induced obese rats, the higher PTT-A dose achieved 19% body weight reduction versus the vehicle, compared to 12% each for tirzepatide and cagrilintide + semaglutide (CagriSema). Body composition analysis showed fat-mass loss without lean-mass loss, distinguishing PTT-A's profile from tirzepatide's documented muscle-loss pattern. PTT-A also showed robust glucose lowering, plasma lipid improvement, insulin sensitization, and liver-fat benefits.
A real-world comparison of tirzepatide and semaglutide for obesity by Venkatakrishnan and colleagues, published in PNAS Nexus on June 16, reported mean body-weight reductions of 14.7% on tirzepatide versus 10.8% on semaglutide at one year. The tirzepatide arm produced close to twice the proportion of 'high responders' (more than 15% body-weight loss) and lower rates of GI events, headache, and fatigue. Female and white patients responded more strongly on either drug than male, black, or Hispanic patients, who were more frequently in the under-5% weight-loss tier. The findings track with SURMOUNT-5's head-to-head trial result and the April 13 OMA Truveta poster but add a new demographic-disparity dimension that should inform real-world treatment selection.
A research team from University Hospitals Coventry and Warwickshire and Warwick Medical School presented meta-analysis data from randomized controlled trials at ENDO 2026 on June 14 showing that 24 weeks of GLP-1 receptor agonist treatment improved testosterone levels, sperm count, and sperm morphology in men ages 18 to 65 with obesity-related low testosterone. Principal investigator Pratibha Natesh proposed reduced inflammation and metabolic stress as candidate mechanisms, with the GLP-1 class potentially preferable to testosterone replacement therapy in this population because TRT can suppress endogenous sperm production. The findings were drawn from men with high BMI, so external validity to normal-weight populations is unclear.
At ADA 2026 on Sunday June 7, Innovent presented the Phase 3 GLORY-2 trial of mazdutide 9 mg in Chinese adults with obesity, presented by Leili Gao of Peking University People's Hospital. The dual GLP-1/glucagon agonist drove up to 20.1% mean weight loss and met its primary endpoint and all key secondary endpoints. The result extends China's homegrown obesity-peptide leadership, with mazdutide already approved by China's NMPA in 2025.
At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.
Boehringer Ingelheim and Zealand Pharma presented the full Phase 3 SYNCHRONIZE-1 readout for survodutide, the glucagon/GLP-1 dual agonist, at ADA 2026. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% placebo (p<0.0001), with up to 85.1% achieving at least 5% loss. Analyst attention now turns to body composition and liver-fat substudies, with reductions driven largely by fat-tissue loss rather than lean mass.
Roche will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide as an ADA 2026 late-breaker, with a June 8 investor event. In 493 adults with overweight or obesity (mean BMI 37), once-weekly petrelintide produced up to 10.7% mean weight loss at week 42 versus 1.7% on placebo, with treatment discontinuation of 4.8% versus 4.9% on placebo and no vomiting or GI-related discontinuations at the maximally effective dose. That tolerability is the amylin class's central pitch against the incretins.
Full Phase 3 SYNCHRONIZE-1 results for the glucagon/GLP-1 dual agonist survodutide are set for ADA 2026, detailing the obesity readout first toplined in April. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% on placebo, with up to 85.1% of treated patients losing at least 5% of body weight. The full dataset puts survodutide's glucagon component, which adds energy expenditure and liver-fat effects, in front of the field that gathers in New Orleans.
Verdiva Bio will present two posters at ADA 2026 on its obesity pipeline: VRB-103, a once-weekly oral amylin-receptor-selective analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist. The preclinical data extend the amylin and oral-peptide push from a well-funded newer entrant, as the obesity field broadens beyond incretin monotherapy toward amylin-based and oral approaches.
Structure Therapeutics will present five obesity and diabetes studies at ADA 2026, anchored by its once-daily oral small-molecule GLP-1 aleniglipron, which posted up to 16.3% placebo-adjusted weight loss at 44 weeks in the Phase 2 ACCESS II trial, among the highest reported for an oral GLP-1. The company has FDA end-of-Phase-2 alignment and plans to start a Phase 3 obesity trial in Q3 2026, with amylin and combination data also on the slate.
A separate ASCO 2026 analysis examined outcomes in patients with breast cancer and co-existing obesity or type 2 diabetes who received GLP-1 receptor agonists — adding breast-cancer-specific depth to the broader GLP-1-and-cancer signal that ran through the meeting. The analysis sits alongside Abstract 3143 (the 12,112-patient study showing 38-50% lower metastatic progression across four obesity-related cancers, with breast cancer at 10% vs 20% metastasis on GLP-1 vs gliptin) and the Roswell Park aggressive-breast-cancer analysis. The consistent theme across the ASCO 2026 GLP-1 oncology slate: in obesity-related and metabolically-driven cancers, GLP-1 therapy appears associated with better outcomes, with the strongest and most mechanistically interpretable signal in breast cancer where high tumor GLP-1 receptor expression tracked with 45% lower mortality. Adverse-event rates matched the comparator groups with no increase in pancreatitis or other GLP-1-associated concerns in the cancer setting. The data is observational and not yet RCT-grade, but the breast-cancer consistency across multiple independent analyses strengthens the case for prospective study.
Eli Lilly announced TRIUMPH-1 topline results May 21 from the 80-week Phase 3 registrational trial of retatrutide — a first-in-class GIP/GLP-1/glucagon triple-receptor agonist — in 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. Mean body weight loss was 28.3% (70.3 lbs) at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg, all versus 2.2% on placebo. All three doses met the primary and key secondary endpoints. 45.3% of participants achieved ≥30% weight loss — bariatric-surgery territory. A 104-week extension in adults with baseline BMI ≥35 saw mean weight loss reach 30.3% (85.0 lbs) on 12 mg. Full data presentation is scheduled for ADA 2026 in New Orleans (June 5-8). Lilly's NDA filing follows the TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + established cardiovascular disease) readouts expected later in 2026.
Two of the year's biggest peptide-related meetings open within 24 hours of each other next week. The European Congress on Obesity 2026 runs May 12–15 in Istanbul, with Novo Nordisk presenting 52 abstracts spanning Wegovy 7.2 mg full STEP UP data, CagriSema higher-dose Phase 3 plans, Wegovy pill efficacy and tolerability, and women's-obesity / perimenopause / migraine subgroups; the 21-expert global panel will also formally propose the 10-year prospective GLP-1 cancer-prevention trial. TIDES USA 2026 runs May 11–14 in Boston with six concurrent scientific tracks across oligonucleotides, peptides, and mRNA — featuring Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk on the CMC strategy and GMP capacity panels. Hims & Hers prints Q1 May 11 the same evening.
Novo Nordisk's Q1 print clarified that Wegovy HD (semaglutide 7.2 mg injection) — approved by the FDA in March and launched in the US on April 7 — is contributing to the premium-tier injectable mix alongside the standard 2.4 mg dose. The STEP UP trial showed 21% mean weight loss at 72 weeks if all patients stayed on treatment (19% regardless), with 89% on 7.2 mg achieving ≥5% body-weight reduction versus 38% with placebo. The label requires four-plus weeks of tolerability on semaglutide 2.4 mg before stepping up. NovoCare prices the 7.2 mg dose at $399/month self-pay and as low as $25 for many commercially insured patients via the savings offer. Dysesthesia at 22% on 7.2 mg vs. 6% on 2.4 mg and 0.3% on placebo is the only meaningful safety signal beyond the broader GLP-1 class.